Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.30 EUR
Change Today -0.004 / -0.17%
Volume 62.0K
PA8 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 8:50 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Open
€2.27
Previous Close
€2.30
Day High
€2.31
Day Low
€2.25
52 Week High
09/23/14 - €3.43
52 Week Low
10/10/14 - €1.66
Market Cap
116.4M
Average Volume 10 Days
264.7K
EPS TTM
€-0.32
Shares Outstanding
50.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

Paion AG, a specialty pharma company, develops and commercializes drug candidates for diseases or interventions. Its product candidates include Remimazolam, an ultra short-acting general anaesthetic/sedative agent, which is under various clinical studies and developed to be used in general anesthesia (deep and long sedation of up to several hours) and procedural sedation (short sedation of up to about 30 minutes) in short procedures, such as colonoscopies applications; and Glial Growth Factor 2 that completed Phase I trials to stimulate the growth and differentiation of various cells, including glial cells. Paion AG was founded in 2000 and is headquartered in Aachen, Germany.

21 Employees
Last Reported Date: 03/18/15
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €370.0K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €340.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €50.0K
Compensation as of Fiscal Year 2014.

paion ag (PA8) Key Developments

PAION AG Appoints Dr. Juergen Raths as New Member of the Management Board and Chief Operating Officer with Effect from 1 September 2015

PAION AG announced that Dr. Juergen Raths has been appointed by the Supervisory Board as a new member of the Management Board of PAION AG and will be Chief Operating Officer with effect from 1 September 2015. Dr. Raths has been working for PAION as a consultant since 2014 and will be responsible for the establishment of the commercial structure to serve anesthetists in Europe and around the world. Dr. Raths has over 25 years of experience in the European and global pharma business, with positions held in medical sales and marketing as well as general management in Europe and the U.S He was Associate Partner with Executive Insight. Dr. Raths focused on supporting Pharma companies entering the European market.

Paion AG Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

Paion AG reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported negative result of EUR 6,637,000 or EUR 0.13 per basic and diluted share on revenues of EUR 6,000 compared to negative result of EUR 1,629,000 or EUR 0.05 per basic and diluted share on revenues of EUR 1,517,000 a year ago. For the first half of 2015, the company reported negative result of EUR 11,340,000 or EUR 0.22 per basic and diluted share on revenues of EUR 39,000 compared to negative result of EUR 3,836,000 or EUR 0.13 per basic and diluted share on revenues of EUR 1,521,000 a year ago. Cash flow used in operating activities was EUR 12,033,000 compared to EUR 5,300,000 a year ago. The company further concentrates on the development of Remimazolam and does not expect significant revenues in 2015. Due to the investments in the development of Remimazolam, research and development expenses will be higher than in 2014 and amount to approximately EUR 25 million to EUR 30 million dependent on the progress of the development. In this context, tax credits on parts of the research and development expenses from British tax authorities in the amount of approximately EUR 5 million to EUR 6 million are expected. General administrative and selling expenses will increase compared to the prior year and amount to approximately EUR 5.5 million, in particular due to higher selling expenses. Accordingly, the net loss will increase significantly compared to prior year and amount to approximately EUR 25 million to EUR 29 million.

Paion Starts EU Phase III Study with Remimazolam in the Indication General Anesthesia

PAION AG, announced the initiation of an EU Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic in the indication 'general anesthesia'. The now starting phase III study is a multi-national, multicenter, randomized, single-blind, propofol-controlled, confirmatory study in patients undergoing major cardiac surgery. The objective is to receive further data to evaluate efficacy, safety and pharmacokinetics of Remimazolam. The primary endpoint is successful anesthesia as measured by meeting a pre-defined level of sedation depth without the use of rescue medication. After end of surgery, patients will be transferred to the post anesthesia care unit (PACU) or the intensive care unit (ICU), with the option to continue Remimazolam treatment for up to 24 hours if required. A total of 530 patients will be treated in several European study centers. Results of the study are expected in 2016. The study is designed to provide further information about the cardiovascular tolerability profile of Remimazolam. Furthermore, it is expected that further insights on the predictable offset of effect as well as the easy control of sedation in the postoperative phase can be gained. Remimazolam will be evaluated against propofol during induction and maintenance of general anesthesia with respect to efficacy and tolerability. Data in the postoperative phase will also be obtained for further exploration of the ICU sedation indication. The study was designed such that the data can be combined with data collected in previous anesthesia studies, including data obtained from trials conducted in Japan. During the Phase II clinical trial in general anesthesia for cardiac surgery, Remimazolam showed an excellent efficacy rate across both treatment groups. As expected, the onset and offset profile of Remimazolam was comparable to propofol/sevoflurane, showing that Remimazolam indeed shares the same fast acting properties. In addition, both the Japanese and the European study demonstrated an improved hemodynamic profile over propofol and the combination propofol/sevoflurane. In the Phase III program in Europe, hemodynamic stability will therefore be the key secondary parameter for profiling Remimazolam. Hemodynamic stability (intraoperative drop of blood pressure and vasopressor usage) is an increasing area of special attention as it is linked to clinical outcomes and patient safety. If Remimazolam's Phase III program confirms its positive hemodynamic profile, the drug may offer anesthesists a valuable therapeutic alternative.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.30 EUR -0.004

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies
 

Industry Analysis

PA8

Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.9x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit www.paion.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.